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Background. Severely immunocompromised human immunodeficiency virus (HIV)–infected individuals have high mortality 
shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and “late presenter” phenotypes.
Methods. The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years of age with 
CD4 counts <100 cells/µL initiating ART in Uganda, Zimbabwe, Malawi, and Kenya. Baseline predictors of mortality through 48 
weeks were identified using Cox regression with backwards elimination (exit P > .1).
Results. Among 1711 included participants, 203 (12%) died. Mortality was independently higher with older age; lower CD4 
count, albumin, hemoglobin, and grip strength; presence of World Health Organization stage 3/4 weight loss, fever, or vomiting; and 
problems with mobility or self-care at baseline (all P < .04). Receiving enhanced antimicrobial prophylaxis independently reduced 
mortality (P = .02). Of five late-presenter phenotypes, Group 1 (n = 355) had highest mortality (25%; median CD4 count, 28 cells/
µL), with high symptom burden, weight loss, poor mobility, and low albumin and hemoglobin. Group 2 (n = 394; 11% mortality; 
43 cells/µL) also had weight loss, with high white cell, platelet, and neutrophil counts suggesting underlying inflammation/infec-
tion. Group 3 (n = 218; 10% mortality) had low CD4 counts (27 cells/µL), but low symptom burden and maintained fat mass. The 
remaining groups had 4%–6% mortality.
Conclusions. Clinical and laboratory features identified groups with highest mortality following ART initiation. A screening 
tool could identify patients with low CD4 counts for prioritizing same-day ART initiation, enhanced prophylaxis, and intensive 
follow-up.
Clinical Trials Registration. ISRCTN43622374.
Keywords. HIV; Africa; immunosuppression; mortality.
World Health Organization (WHO) guidelines recommend uni-
versal antiretroviral therapy (ART) irrespective of CD4 count 
[1–3]. However, in sub-Saharan Africa, 20%–25% of human 
immunodeficiency virus (HIV)–infected individuals still pres-
ent for care with severe immunosuppression (CD4 count <100 
cells/µL) [4], of whom approximately 10% die within 3 months 
of ART initiation [5–8]. Early mortality is markedly higher in 
adults and children with low CD4 count or lower body mass 
index (BMI), even above levels indicating severe malnutrition 
[7–9], or with low hemoglobin level [8].
A recent analysis of 850 HIV-infected adults/adolescents 
initiating ART with CD4 count <50 cells/µL, randomized to 
receive empiric tuberculosis treatment or isoniazid preventive 
therapy, identified higher mortality in those with lower CD4 
cell count, albumin, and hemoglobin; higher white blood cell 
(WBC) count or neutrophil percentage; or lymphadenopathy 
[10]. Given the substantial numbers presenting with low CD4 
cell count and their high mortality shortly after ART initiation, 
additional studies in “late presenters” are important to identify 
their key characteristics, particularly if baseline CD4 count test-
ing is not always available, to identify them earlier at healthcare 
facilities and prioritize them for additional interventions.
We therefore investigated predictors of mortality in the first 48 
weeks on ART, and characterized different patterns of late pres-
entation in adults and older children enrolled in the Reduction 
in EArly MortaLITY (REALITY) trial (ISRCTN43622374).
METHODS
REALITY recruited previously untreated adults and children 
aged ≥5 years with a CD4 count <100 cells/µL from 8 centers 
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in Kenya, Malawi, Uganda, and Zimbabwe [11]. Pregnancy or 
breastfeeding were trial exclusion criteria. Participants were ran-
domized 1:1 to each of 12 weeks of raltegravir vs no raltegravir; 
enhanced prophylaxis vs standard prophylaxis (cotrimoxazole); 
and 12 weeks of ready-to-use supplementary food vs standard 
nutritional support, together with WHO-recommended com-
bination ART. Enhanced prophylaxis consisted of cotrimoxa-
zole plus isoniazid, pyridoxine, and fluconazole for 12 weeks, 
azithromycin for 5 days, and a single dose of albendazole [11]. 
Adults and children’s guardians gave written informed con-
sent; older children gave additional assent following national 
guidelines. The trial was approved by ethics committees in 
Zimbabwe, Uganda, Malawi, Kenya, and the United Kingdom.
At screening and enrollment, patients underwent a physical 
examination including height, weight, mid-upper arm circum-
ference (MUAC), body composition assessment by bioim-
pedance analysis (TANITA BC-420MA), and assessment for 
WHO stage 3/4 events, including tuberculosis symptom screen 
and diagnostic tests as indicated. Concomitant medications, 
including reason for prescription, were also recorded at both 
visits. At enrollment, blood pressure and grip strength (Takei 
5401 Hand Grip Dynamometer) were measured, and partici-
pants were administered a symptom checklist and EuroQol 5 
Dimensions (EQ-5D) questionnaire. Full blood count, tests of 
renal and liver function, and lymphocyte subsets were assayed at 
screening and enrollment in real time and samples were stored 
at enrollment for retrospective HIV viral load (VL) assays.
Statistical Analysis
Baseline demographics, laboratory results, physical measure-
ments, and EQ-5D scores were all considered as predictors of 
mortality during the first 48 weeks on ART, after which partic-
ipants exited the trial (Table 1; Supplementary Table 1; details 
in Supplementary Methods). Factors were selected for the final 
Cox proportional hazards model using backwards elimination 
(exit P > .1 to build an explanatory model, reporting only fac-
tors with P < .05) and incorporating any significant nonlinearity 
(Stata mfp). Clinical center (reflecting clinical management and 
access to diagnostic facilities) was included in all models. Models 
were restricted to complete cases. Different patterns of late pre-
senters were identified using hierarchical cluster analysis deter-
mining the number of clusters using the Duda-Hart stopping 
rule [12] (details are shown in the Supplementary Methods). 
Analysis was performed using Stata software version 14.2.
RESULTS
A total of 1805 participants were recruited, 40 (2%) aged 
<13 years, all previously untreated and with CD4 count <100 
cells/µL at screening following the trial design, and hence con-
sidered late presenters. Two hundred twenty-five (12%) died 
before 48 weeks, a median of 8 weeks (interquartile range [IQR], 
3–18 weeks) after ART initiation. Only 56 (3%) participants were 
lost to follow-up. Although 1674 (93%) participants reported an 
HIV test prior to trial screening, the time since this test was very 
short (median, 14 days; IQR, 6–39 days). Participants who died 
were slightly older (median, 37 vs 36 years; P = .005; Table 1) 
and had significantly lower baseline CD4 counts (median, 25 
vs 38 cells/µL; P <  .001). Excepting platelets, all other labora-
tory tests differed significantly in those who died (P  <  .01): 
Hemoglobin, albumin, and estimated glomerular filtration rate 
(Cockcroft-Gault formula) were all lower in those who died 
whereas HIV VL, WBC count, and neutrophils were higher. 
All baseline physical measurements and BMI were significantly 
lower in those who subsequently died (P <  .001), particularly 
grip strength (median, 20.0 vs 25.1 kg) and fat mass (median, 
4.6 vs 6.7 kg). All symptoms except rash were reported more at 
enrollment in those who subsequently died (P < .01), and they 
were significantly more likely to suffer from WHO stage 3/4 
weight loss and tuberculosis (P  <  .01) at enrollment. Patients 
who died were significantly more likely to report moderate or 
extreme problems for EQ-5D (P < .001).
Final multivariable models included 1711 participants (26 
aged <13  years), of whom 203 (12%) died. Mortality was in-
dependently higher in those who were older (P  =  .002), with 
lower CD4 counts (P < .001), lower albumin (P = .001), lower 
hemoglobin (P  =  .01), and weaker grip strength (P  =  .03); 
those in whom physicians reported WHO stage 3/4 weight 
loss (P = .04); and in those patients reporting fever (P = .001), 
vomiting (P  =  .02), some problems with mobility (P  =  .005), 
and inability to wash or dress themselves (P  =  .003) at base-
line (Table 2). Receiving enhanced prophylaxis independently 
reduced mortality (P =  .02) (as overall in [11]), but receiving 
raltegravir (P  =  .60) and ready-to-use supplementary food 
(P = .37) did not, and were not included in the final model. The 
area under the receiver operating curve was 80% (95% confi-
dence interval, 76%–83%), supporting good model discrimin-
ation. CD8 cell count was not considered in this multivariable 
model as this would have excluded an additional 108 (6%) par-
ticipants; however, CD8 cell count was not associated with mor-
tality after adjusting for other factors in Table 2 (P = .41).
We then considered whether the risk factors mentioned above 
clustered in specific groups of patients, that is, whether late present-
ers could be phenotyped according to their pre-ART characteris-
tics. Five groups of the 1607 participants with complete data for all 
factors in Table 1 were identified through clustering. Group 1 had 
the highest mortality (25% [87/355]; 18% by week 12) and were 
characterized by high burden of problems reported on the EQ-5D, 
particularly for mobility (78% vs 20% overall), self-care (71% vs 
18%), and usual activities (93% vs 29%; Supplementary Table 2; 
represented visually in Figure 1). Excluding rash, they also had 
the highest burden of symptoms and illness, especially weight loss, 
difficulty walking, and poor appetite.
Other groups had significantly lower, but still substantial, 
mortality. Group  2 (n  =  394; 11% [45] deaths; 7% by week 
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Table 1. Characteristics at Antiretroviral Therapy Initiation
Characteristic
Died Before 48 wk  
(n = 225)
Last Seen Alive  
(n = 1580)
All Participants  
(N = 1805)
Univariable  
P Valuea
Male sex 109 (48) 852 (54) 961 (53) .12
Age, y 37 (30–44) 36 (29–41) 36 (29–42) .005
Age 5–17 y 4 (2) 68 (4) 72 (4)
Center <.001
 Blantyre, Malawi 25 (11) 230 (15) 255 (14)
 Harare, Zimbabwe 51 (23) 518 (33) 569 (32)
 Kilifi, Kenya 29 (13) 114 (7) 143 (8)
 Eldoret, Kenya 14 (6) 194 (12) 208 (12)
 Fort Portal, Uganda 28 (12) 114 (7) 142 (8)
 Mbale, Uganda 25 (11) 94 (6) 119 (7)
 Mbarara, Uganda 26 (12) 203 (13) 229 (13)
 Gulu, Uganda 27 (12) 113 (7) 140 (8)
Smoking status (n = 1795) .86
 Never 180 (80) 1269 (81) 1449 (81)
 Ever 45 (20) 301 (19) 346 (19)
Blood pressure (systolic/diastolic), mm Hg 
(n = 1767)
102/69 (93/60–110/75) 109/70 (100/63–119/78) 108/70 (99/63–118/77) SBP <.001; DBP .006
BMI, kg/m2 (n = 1797) 18.0 (16.2–19.8) 19.3 (17.4–21.6) 19.2 (17.2–21.4) <.001
MUAC, cm (n = 1804) 22.6 (20.2–24.7) 24.0 (22.0–26.3) 24.0 (21.8–26.0) <.001
Grip strength, kg (n = 1772) 20.0 (15.3–25.6) 25.1 (19.9–31.4) 24.5 (19.3–31.0) <.001
Fat mass, kg (n = 1743) 4.6 (1.8–8.9) 6.7 (3.8–12.5) 6.5 (3.6–12.2) <.001
Fat-free mass, kg (n = 1743) 40.9 (37.2–47.3) 43.9 (39.4–49.7) 43.5 (39.0–49.4) <.001
HIV VL, copies/mL (n = 1790) 332 260 (132 020–1 000 000) 240 000 (93 000–554 010) 249 765 (95 630–606 310)
Log10 HIV VL (n = 1790) 5.5 (5.1–6.0) 5.4 (5.0–5.7) 5.4 (5.0–5.8) <.001
CD4 count, cells/µL 25 (10–51) 38 (17–64) 37 (16–63) <.001
Hemoglobin, g/dL (n = 1802) 10.0 (8.4–11.6) 11.4 (9.7–12.8) 11.2 (9.6–12.7) <.001
WBC count, 109/L (n = 1802) 3.9 (2.9–5.4) 3.5 (2.7–4.6) 3.5 (2.7–4.7) <.001
Platelets, 109/L (n = 1801) 260 (189–341) 251 (182–343) 252 (183–343) .88
Neutrophils, 109/L (n = 1785) 1.99 (1.38–3.07) 1.69 (1.15–2.50) 1.72 (1.17–2.58) <.001
Albumin, g/L (n = 1755) 30 (26–35) 35 (31–40) 35 (30–40) <.001
eGFRb, mL/min (n = 1793) 85.3 (60.4–111.3) 98.8 (79.3–122.4) 97.3 (77.3–121.1) <.001
Hospitalized at randomization 11 (5) 11 (1) 22 (1) <.001
Previous healthcare contactc 23 (10) 140 (9) 163 (9) .50
Patient-reported symptoms at enrollment
 Fever 70 (31) 170 (11) 240 (13) <.001
 Weight loss 147 (65) 759 (48) 906 (50) <.001
 Difficulty walking 86 (38) 148 (9) 234 (13) <.001
 Rash 34 (15) 291 (18) 325 (18) .22
 Numbness 60 (27) 293 (19) 353 (20) .004
 Abdominal ache 39 (17) 157 (10) 196 (11) .001
 Sore mouth 34 (15) 148 (9) 182 (10) .004
 Vomiting 39 (17) 75 (5) 114 (6) <.001
Physician-assessed illnesses
 Current wasting/severe weight loss (WHO stage 
3/4)
64 (28) 263 (17) 327 (18) <.001
 Current TB (all) (WHO stage 3/4) 48 (21) 223 (14) 271 (15) .003
 Current Candida infection (WHO stage 3/4) 17 (8) 82 (5) 99 (5) .10
EQ-5D
 Mobility (n = 1791) <.001
  No problems walking 102 (46) 1297 (83) 1399 (78)
  Some problems walking 103 (47) 261 (17) 364 (20)
  Confined to bed 16 (7) 12 (1) 28 (2)
 Self-care (n = 1791) <.001
  No problems washing/dressing 110 (50) 1318 (84) 1428 (80)
  Some problems washing/dressing 74 (33) 212 (14) 286 (16)
  Unable to wash/dress myself 37 (17) 40 (3) 77 (4)
 Usual activities (n = 1791) <.001
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12) had high levels of WBCs, platelets, and neutrophils, despite 
lower levels of reported fever (12%) than group 1 (28%). Only 
122 (31%) had an infection reported at enrollment, suggesting 
they may have had underlying infections or inflammation. This 
group also had substantial weight loss and low fat mass, and low 
BMI, albumin, and hemoglobin, similar to group 1. However, 
median CD4 cell count was higher in group 2 vs group 1 (43 vs 
28 cells/µL) as was grip strength (median, 24.5 vs 20.0 kg).
Group  3 (n  =  242; 10% [25] deaths; 5% by week 12)  were 
mainly (nonpregnant, nonbreastfeeding) females (76%) and 
younger (median, 30 vs 36  years overall). They had low CD4 
counts (median, 27 cells/µL), WBCs, neutrophils, hemoglobin, 
BMI, MUAC, and grip strength, but despite this had low burden 
of symptoms/illnesses and maintained a reasonable fat mass 
and higher albumin. Group  4 (n  =  218; 6% [12] deaths) was 
also mostly female (97%), but differed from group 3 in being 
older (median, 36 vs 30  years) with higher CD4 cell counts 
(median, 48 vs 27 cells/µL) and much higher fat mass (median, 
18.9 vs 7.1 kg in group 3; 6.6 kg overall), with correspondingly 
higher BMI and MUAC. Group 5 (n = 398; 4% [15] deaths) was 
predominately male (86%) and older (median, 39 years) with 
higher fat mass, fat-free mass, and grip strength, and a median 
CD4 count of 42 cells/µL.
Cluster significantly predicted mortality univariably 
(P < .001), but not after adjusting for the factors shown in Table 2 
(P  =  .18), as expected since the clusters were predominantly 
differentiated by clinical factors (Supplementary Table 2). There 
was no evidence that the effect of enhanced prophylaxis on 
mortality varied across the clusters (interaction P  =  .32), nor 
did the effect of adjunctive raltegravir (P = .20) or supplemen-
tary food (P = .66).
DISCUSSION
Using data from a large African trial in which 12% of HIV-
infected adults and older children with a CD4 count <100 cells/
µL died during the 48 weeks following ART initiation, we con-
firm the importance of weight loss, clinical symptoms, and 
activities of daily living as predictors of mortality, independent 
of low CD4 cell counts. Low hemoglobin and albumin were the 
only laboratory prognostic markers of early mortality in these 
late presenters, in addition to CD4 cell count, as in another 
smaller recent study [10]. However, we identified a constellation 
of clinical symptoms and other laboratory markers which char-
acterized subgroups of patients at even higher mortality risk.
As we collected data on a large number of clinical and lab-
oratory parameters (Table 1; Supplementary Table 1), we were 
able to identify a more detailed and slightly different set of clin-
ical predictors to a recent analysis of a smaller trial with lower 
mortality (7%) [10]. Interestingly, high HIV VL and WBC 
count, but not neutrophil percentage, were independent pre-
dictors of mortality in REALITY participants when fitting the 
prognostic model from this previous study (Table 2). However, 
Characteristic
Died Before 48 wk  
(n = 225)
Last Seen Alive  
(n = 1580)
All Participants  
(N = 1805)
Univariable  
P Valuea
  No problems with usual activities 91 (41) 1160 (74) 1251 (70)
  Some problems with usual activities 80 (36) 319 (20) 399 (22)
  Unable to do usual activities 50 (23) 91 (6) 141 (8)
 Pain/discomfort (n = 1791) <.001
  No pain/discomfort 93 (42) 1009 (64) 1102 (62)
  Moderate pain/discomfort 116 (52) 517 (33) 633 (35)
  Extreme pain/discomfort 12 (5) 44 (2) 56 (3)
 Anxiety (n = 1791) <.001
  Not anxious/depressed 121 (55) 1191 (76) 1312 (73)
  Moderately anxious/depressed 89 (40) 348 (22) 437 (24)
  Extremely anxious/depressed 11 (5) 31 (2) 42 (2)
WHO stage <.001
 1 22 (10) 278 (18) 300 (17)
 2 44 (19) 510 (32) 554 (31)
 3 105 (47) 586 (37) 691 (38)
 4 54 (24) 206 (13) 260 (14)
Randomized to enhanced prophylaxis 98 (44) 808 (51) 906 (50) .03
Randomized to adjunctive raltegravir 110 (49) 792 (50) 902 (50) .77
Randomized to adjunctive ready-to-use food 111 (49) 786 (50) 897 (50) .94
Data are presented as No. (%) or median (interquartile range).
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EQ-5D, EuroQol 5 Dimensions (score); HIV, human immunodeficiency virus; 
MUAC, mid-upper arm circumference; SBP, systolic blood pressure; TB, tuberculosis; VL, viral load; WBC, white blood cell; WHO, World Health Organization.
aFrom Cox model.
bEstimated using Cockcroft-Gault formula.
cChronic health conditions or prescribed medications >14 days prior to screening visit.
Table 1. Continued
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other clinical factors were more predictive than these labora-
tory parameters in REALITY participants. In particular, once 
problems with mobility were included as a prognostic factor, 
there was no additional association between HIV VL and mor-
tality, suggesting that mobility may be a broad physical marker 
for the detrimental impact of ongoing viral replication. There 
was a marginal association between WBC and mortality in our 
final model, supporting infection and/or inflammation playing 
a role in early increased mortality risk. These clinical factors are 
not part of traditional WHO staging, which is based on defined 
illnesses, but may be helpful for triaging patients at high risk of 
early mortality on ART for more intensive monitoring and/or 
support, particularly in lower-level health facilities when access 
to laboratory tests is limited.
We previously showed that a package of enhanced prophy-
laxis reduced mortality by 27% during the first 24 weeks of ART 
in this population with low CD4 counts [11]. Here, we found no 
evidence that any group benefited more from enhanced proph-
ylaxis, although power was limited to detect greater benefits in 
specific subgroups. It is therefore important that CD4 mon-
itoring is available in health facilities to identify late present-
ers, particularly as almost half of participants in this trial had 
minimal clinical symptoms, in particular the predominantly 
young female group 3 with very low CD4 cell counts. Simple 
questions about fever, vomiting, weight loss, and activities of 
daily living (in the EQ-5D) identified those at particularly high 
risk of mortality who should be prioritized for immediate treat-
ment (eg, same-day ART initiation), enhanced prophylaxis, and 
more intensive follow-up.
Rather than late presenters being a homogenous group, we 
identified 5 phenotypes, with several prognostic factors var-
ying substantially across groups, as did mortality. One group 
had very high mortality (25%), with high levels of wasting and 
clinical symptoms, and low CD4 count (median, 28 cells/µL), 
hemoglobin, and albumin, reflecting “traditional” HIV disease, 
but very high impairment of activities of daily living. There was 
no evidence that adjunctive raltegravir or supplementary food 
had any beneficial effects in this subgroup at particularly high 
mortality risk. Despite similarly low CD4 cell count (median, 
27 cells/µL), hemoglobin, and BMI, another group of predom-
inantly younger women without clinical symptoms had signif-
icantly lower mortality (although this was still 10%). Another 
group with 11% mortality had high WBCs, platelets, and neu-
trophils, suggesting possible underlying infection or chronic 
Table 2. Independent Predictors of Mortality in the First 48 Weeks on Antiretroviral Therapy Initiated With CD4 Count <100 Cells/µL
Factor
Univariable Effects of Factors 
Selected for Multivariable Model in 
REALITY Trial Participants
Final Multivariable Model in 
REALITY Trial Participants
Multivariable Model From Bisson 
et al [10], Fitted to REALITY Trial 
Participants
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age (per 5 y older) 1.09 (1.03–1.16) .005 1.12 (1.04–1.20) .002 1.13 (1.06–1.21) <.001
CD4 (per 10 cells/µL higher) 0.89 (.85–.94) <.001 0.90 (.85–.95) <.001 0.87 (.82–.92) <.001
Hemoglobin (per g/dL higher) 0.77 (.72–.82) <.001 0.90 (.83–.99) .01 0.87 (.80–.94) <.001
Albumin (per g/L higher) 0.92 (.90–.93) <.001 0.96 (.94–.98) .001 0.94 (.92–.97) <.001
WBC count (per 109/L higher) 1.17 (1.08–1.26) <.001 1.08 (1.00–1.17) .054 1.16 (1.06–1.25) .001
Grip strength (per kg higher) 0.93 (.91–.95) <.001 0.98 (.96–1.00) .03 …
Previous healthcare contact 1.16 (.75–1.79) .50 0.63 (.39–1.03) .067 …
WHO stage 3/4 weight loss 1.90 (1.42–2.53) <.001 1.43 (1.01–2.03) .04 …
Patient-reported fever 3.37 (2.54–4.47) <.001 1.67 (1.19–2.35) .003 …
Patient-reported vomiting 3.72 (2.64–5.26) <.001 1.55 (1.00–2.39) .048 …
EQ-5D Mobility: some problems  
vs no problems
4.42 (3.36–5.81) <.001 1.88 (1.21–2.93) .005 …
Confined to bed vs no problems 11.87 (7.00–20.12) <.001 2.47 (1.00–6.08) .050 …
EQ-5D Self-care: some problems  
vs no problems
3.73 (2.78–5.02) <.001 1.32 (.82–2.13) .26 …
Unable to wash/dress  
vs no problems
8.59 (5.91–12.47) <.001 2.78 (1.42–5.43) .003 …
Enhanced prophylaxis 0.75 (.57–.97) .03 0.72 (.54–.96) .02 …
Sex (female vs male) 1.23 (.95–1.60) .12 … 1.19 (.89–1.60) .23
BMI <18.5 vs >25 kg/m2 2.41 (1.30–4.48) .005 … 0.90 (.52–1.55) .70
BMI 18.5–25 vs >25 kg/m2 1.38 (.74–2.58) .32 … 0.70 (.41–1.19) .19
HIV VL (per log10 higher) 1.52 (1.22–1.89) <.001 … 1.37 (1.09–1.74) .008
Neutrophil % (per 5% higher) 1.07 (1.02–1.12) .003 … 0.99 (.95–1.04) .64
Final multivariable model in REALITY trial participants also adjusted for center. Backwards elimination (exit P < .1) on factors in Table 1, refitting final model to all observations with complete 
data for chosen factors. Factors with P > .05 are included to adjust for confounding. All continuous factors were selected in final models with linear effects, ie, each unit increase had the 
same impact on mortality at all levels of the factor.
Abbreviations: BMI, body mass index; CI, confidence interval; EQ-5D, EuroQol 5 Dimensions (score); HIV, human immunodeficiency virus; HR, hazard ratio; REALITY, Reduction in EArly 
MortaLITY (trial); VL, viral load; WBC, white blood cell; WHO, World Health Organization.
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inflammation. Future substudies will evaluate how inflamma-
tory markers such as C-reactive protein and interleukin 6 vary 
between groups, as baseline inflammation independently pre-
dicts mortality in adults and children [13–15]. We speculate 
that groups 1 and 2 have the highest inflammation, which can 
inhibit protein synthesis and bone marrow activity, leading to 
low albumin and hemoglobin, and drive cachexia through loss 
of lean mass. In contrast, the other 3 groups had managed to 
maintain their weight and body composition (fat mass in par-
ticular), despite substantial CD4 impairment, suggesting lower 
levels of inflammation. Among patients with similar CD4 cell 
counts, heightened inflammation may drive higher mortality 
in a subgroup, who might be identified through weight loss, 
anemia, and hypoalbuminemia.
In summary, a substantial proportion of HIV-infected indi-
viduals continue to present for care with advanced immuno-
suppression. CD4 counts are important to identify those who 
would benefit from additional interventions [16] with ART, 
such as enhanced antimicrobial prophylaxis [11], particularly 
as many present to care without clinical symptoms. Here, we 
show that clinical and laboratory characteristics could identify 
groups with highest risk of mortality following ART initia-
tion, despite similarly low CD4 cell counts. Screening patients 
with low CD4 counts at baseline for significant weight loss, a 
small cluster of important symptoms (eg, fever and vomiting), 
impairment of activities of daily living, and a simple assessment 
of grip strength might identify those at highest risk of death. At 
higher-level health facilities, additional laboratory tests (albu-
min and hemoglobin) would also help to stratify high-risk 
individuals. A  screening tool appropriate to the level of facil-
ity could therefore help identify which patients with low CD4 
cell counts should be prioritized, for example, for same-day 
ART and enhanced prophylaxis initiation or more intensive 
follow-up.
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Figure 1. Summary of characteristics of different patterns of late presenters. A, Categorical factors. B, Continuous factors. Percentage of participants who died in each 
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Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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